Full Text View
Tabular View
Study Results
Related Studies
Efficacy and Safety Study of Augmentation Therapy With ARALAST Fraction IV-1 (Human Alpha 1 - Proteinase Inhibitor)
This study has been completed.
Study NCT00396006   Information provided by Baxter Healthcare Corporation

First Received on November 3, 2006.   Last Updated on March 3, 2011   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Alpha 1-Antitrypsin Deficiency
More general conditions related to this trial
Digestive System Diseases
Emphysema
Genetic Diseases, Inborn
Liver Diseases
Lung Diseases
Pathologic Processes
Respiratory Tract Diseases
Subcutaneous Emphysema
Interventions listed in this trial
Alpha1-Proteinase Inhibitor
Additional drug interventions recognized in this trial
Alpha 1-Antitrypsin
Protease Inhibitors
More general drug interventions related to this trial
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Serine Proteinase Inhibitors
Trypsin Inhibitors
Sponsors listed in this trial
Baxter Healthcare Corporation


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services